Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision model.

MLA

Furiak, Nicolas M., et al. “Cost-Effectiveness of Olanzapine Long-Acting Injection in the Treatment of Patients with Schizophrenia in the United States: A Micro-Simulation Economic Decision Model.” Current Medical Research and Opinion, vol. 27, no. 4, Apr. 2011, pp. 713–30. EBSCOhost, https://doi.org/10.1185/03007995.2011.554533.

APA

Furiak, N. M., Ascher-Svanum, H., Klein, R. W., Smolen, L. J., Lawson, A. H., Montgomery, W., & Conley, R. R. (2011). Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision model. Current Medical Research and Opinion, 27(4), 713–730. https://doi.org/10.1185/03007995.2011.554533

Chicago

Furiak, Nicolas M, Haya Ascher-Svanum, Robert W Klein, Lee J Smolen, Anthony H Lawson, William Montgomery, and Robert R Conley. 2011. “Cost-Effectiveness of Olanzapine Long-Acting Injection in the Treatment of Patients with Schizophrenia in the United States: A Micro-Simulation Economic Decision Model.” Current Medical Research and Opinion 27 (4): 713–30. doi:10.1185/03007995.2011.554533.